Clinical Trial

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

Study acronym: EMERALD
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-05
Trial Details
NCT Number NCT07010471
Lead Sponsor Praxis Precision Medicines
Conditions Developmental and Epileptic Encephalopathy 1
Enrollment 160 participants
Start Date 2025-07-09
Primary Completion 2026-12 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-04